AA222

FDA registration

DGS Diagnostics Sp. z o.o·1 product·🇵🇱 Poland

REM440

FDA registration

DGS Diagnostics Sp. z o.o·1 product·🇵🇱 Poland

Range+QUALICHECK LEVEL 1,2,3

FDA registration

Radiometer Solutions Sp. z o.o.·1 product·🇵🇱 Poland

ABL90 FLEX

FDA registration

Radiometer Solutions Sp. z o.o.·12 products·🇵🇱 Poland

Ambu® aBox™ 2

FDA registration

AMBU SDN.BHD.·1 product·🇲🇾 Malaysia

Ponto 5 SuperPower

FDA registration

Demant Operations Poland Sp. z o.o.·2 products·🇵🇱 Poland

TCM40 Monitoring System,

FDA registration

Radiometer Solutions Sp. z o.o.·4 products·🇵🇱 Poland

Regulated Decision Support Framework

Basic UDI-DI

EU MDD · Eu Md Class 1 ·Epic Systems Corporation·1 device

Cognitive Computing Clinical Models

Basic UDI-DI

EU MDD · Eu Md Class 1 ·Epic Systems Corporation·1 device

Patient Portal Guidance Framework

Basic UDI-DI

EU MDD · Eu Md Class 1 ·Epic Systems Corporation·1 device

Καλσόν Εγκυμοσύνης 70 Den

Basic UDI-DI

EU MDR · Eu Md Class 1 ·ADCO ORTHOPAEDICS LTD·10 devices

Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer

FDA Pre-Market Approval

FDA Class 3 ·HER2 CISH PHARMDX KIT

Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer

FDA Pre-Market Approval

FDA Class 3 ·HER2 CISH PHARMDX KIT

Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer

FDA Pre-Market Approval

FDA Class 3 ·HER2 CISH PHARMDX KIT

Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer

FDA Pre-Market Approval

FDA Class 3 ·HER2 CISH PHARMDX KIT

Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer

FDA Pre-Market Approval

FDA Class 3 ·HER2 CISH PHARMADX KIT

Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer

FDA Pre-Market Approval

FDA Class 3 ·HER2 CISH PHARMDX KIT

Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer

FDA Pre-Market Approval

FDA Class 3 ·HER2 CISH PHARMDX KIT

Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer

FDA Pre-Market Approval

FDA Class 3 ·HER2 CISH PHARMDX KIT

Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer

FDA Pre-Market Approval

FDA Class 3 ·HER2 CISH PHARMDX KIT